Analytic for Hemodynamic Instability (AHI)

  A computer-aided diagnostic using a single ECG lead to predict hemodynamic instability.

Value Proposition

AHI gives a reliable heads-up about emerging signs of hemodynamic instability, enabling proactive patient rescue. AHI continuously monitors patients with an electrocardiogram (ECG) for hemodynamic instability — a leading cause of death for critically ill or injured patients. This technology enables hemodynamic assessments every two minutes as opposed to every two hours or more, increasing the likelihood of timely patient rescue. Additionally, it provides rapid feedback to clinicians on the viability of their treatments.

Competitive Advantage

Unlike the current approach of monitoring ICU patients at certain intervals, AHI will detect the early onset of hemodynamic instability and alert key personnel to facilitate early intervention and increase patient survival. The technology is non-invasive and is applicable for a diverse array of diseases requiring advanced hemodynamic monitoring in both clinical and non-clinical settings. AHI is the first technology of it’s kind that allows real-time streaming data to alert clinicians to patient instability hours before critical events.

Real-Time Streaming Data
Non-Invasive Technology
Enables Earlier Treatment

Unique Features

Real-Time Streaming Data
Non-Invasive Technology
Allows for earlier intervention
Reduces attending clinician burden
AHI produces an indication of hemodynamic status 93 times more frequently than nurse validated vitals.

These products have established agreements with companies and/or manufacturers.

Licensing Information
FifthEye in 2018

Principal Investigators
Ashwin Belle, PhD
Kevin Ward, MD

Intellectual Property
Invention Disclosure # 6147, 6148, 7024, 7425, 7485, 2018-314, 2018-315
Patent Issued # US20150374300A1

Solution Sheet
Download Solution Sheet (PDF)

INDUSTRY OPPORTUNITY
The AHI software is intended for use by healthcare professionals managing in-hospital patients 18 years or older who are receiving continuous physiological monitoring with ECG. Fifth Eye has received De Novo classification from the FDA. The De Novo grant recognizes the unique nature of AHI while confirming it is both safe and effective. As a result, Fifth Eye can now begin commercialization and marketing of AHI to hospitals throughout the United States.

Contact Fifth Eye for more information about investment and partnership opportunities.